Impax to divest 10 products amid acquisition by Amneal

The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

1 April 2019 Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of its medications from entering the market, the US Federal Trade Commission has ruled.

More on this story

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

More on this story

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

FTC approves Amneal’s $1.45bn acquisition of Impax

11 July 2018 The US Federal Trade Commission has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic